Norrin Restores Blood-Retinal Barrier and Preserves Vision in Diabetic Rats via Wnt Pathway Modulation
Norrin treatment in diabetic rats preserved the blood-retinal barrier, reduced neuronal loss, and maintained vision through a VEGF-independent mechanism. The findings support ongoing clinical development of norrin-pathway modulators but remain limited to rodent models with short follow-up. Human trials will determine whether barrier restoration translates to durable visual benefit.
The Antonetti lab data directly informed EyeBio and Merck programs now in early human testing for norrin-pathway agonists in diabetic macular edema. Remaining questions include durability beyond the 8-week rat observation period, optimal dosing frequency, and whether systemic or topical delivery can achieve retinal concentrations without injection. Large-animal and human safety studies are required before any efficacy claims in patients.
Merck/EyeBio: Phase 2 RESTORE trial will show at least 8-letter mean BCVA gain at 24 weeks in treatment-naive DME patients by mid-2027.
Sources (3)
- [1]Primary Source(https://diabetesjournals.org/diabetes/article/doi/10.2337/db26-0340)
- [2]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMra1416593)
- [3]Supporting Source(https://pubmed.ncbi.nlm.nih.gov/31217346/)